Followers | 182 |
Posts | 12771 |
Boards Moderated | 0 |
Alias Born | 12/08/2009 |
Monday, August 10, 2020 11:58:00 AM
BELLUS Health Reports Full Year 2019 Financial Results
Cash Position: As of December 31, 2019, the Company had available cash, cash equivalents and short-term investments totalling C$116,884,000 (US$89,980,000), compared to C$48,906,000 (US$35,863,000) as at December 31, 2018.
Here is a direct link to the financial report:
https://ir.bellushealth.com/news-releases/news-release-details/bellus-health-reports-full-year-2019-financial-results-and
Solid company that admittedly had a setback on the FDA phase trial. CEO came out and stated they still know their product works but not at the limited threshold of the study. They will push for another phase 2 in 4th quarter and the stock will rebound hard much higher then $12 price before the crash if phase 2 is successful this time. We could see $20++ imo with a successful phase 2. Way oversold and undervalued down here. Go $BLU$
In the RELIEF trial, we observed data that we believe is competitive within the P2X3 class, including the reduction in cough frequency shown in patients with higher cough counts and a low taste effect. While we had hoped to see more response in the lower cough patients, BLU-5937 and other P2X3 antagonists may have the most benefit in patients with a greater disease burden,” said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. “We believe the Phase 2 data support moving BLU-5937 forward into an adaptive Phase 2b trial enriched for higher cough count patients. We expect to begin this trial in the fourth quarter of 2020.”
https://www.otcmarkets.com/stock/BLU/news/story?e&id=1637916
Recent BLU News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/30/2024 03:56:14 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 08/14/2023 09:01:58 PM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 07/10/2023 12:00:11 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 06/28/2023 09:21:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 06:42:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/28/2023 03:05:50 PM
- Annonce boursière - Réservée aux médias et aux investisseurs - GSK mène à terme l'acquisition de BELLUS Santé • PR Newswire (Canada) • 06/28/2023 02:59:00 PM
- Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health • PR Newswire (Canada) • 06/28/2023 02:57:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM